Your browser doesn't support javascript.
loading
Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport.
Obinu, Antonella; Burrai, Giovanni Pietro; Cavalli, Roberta; Galleri, Grazia; Migheli, Rossana; Antuofermo, Elisabetta; Rassu, Giovanna; Gavini, Elisabetta; Giunchedi, Paolo.
Afiliação
  • Obinu A; Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.
  • Burrai GP; Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy.
  • Cavalli R; Mediterranean Center for Disease Control (MCDC), University of Sassari, 07100 Sassari, Italy.
  • Galleri G; Department of Science and Technology of Pharmaceutics, University of Torino, 10125 Torino, Italy.
  • Migheli R; Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
  • Antuofermo E; Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
  • Rassu G; Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy.
  • Gavini E; Mediterranean Center for Disease Control (MCDC), University of Sassari, 07100 Sassari, Italy.
  • Giunchedi P; Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.
Pharmaceutics ; 13(2)2021 Feb 16.
Article em En | MEDLINE | ID: mdl-33669306
ABSTRACT
Genistein (GEN) is a soy-derived isoflavone that exhibits several biological effects, such as neuroprotective activity and the prevention of several types of cancer and cardiovascular disease. However, due to its poor water solubility and the extensive first-pass metabolism, the oral bioavailability of GEN is limited. In this work, solid lipid nanoparticles (SLN) were developed to preferentially reach the intestinal lymphatic vessels, avoiding the first-pass metabolism of GEN. GEN-loaded SLN were obtained by a hot homogenization process, and the formulation parameters were chosen based on already formulated studies. The nanoparticles were characterized, and the preliminary in vitro chylomicron formation was evaluated. The cell uptake of selected nanocarriers was studied on the Caco-2 cell line and intestinal mucosa. The SLN, characterized by a spherical shape, showed an average diameter (about 280 nm) suitable for an intestinal lymphatic uptake, good stability during the testing time, and high drug loading capacity. Furthermore, the intestinal mucosa and Caco-2 cells were found to uptake SLN. The approximately two-fold increase in particle size suggested a possible interaction between SLN and the lipid components of chylomicrons like phospholipid; therefore, the results may support the potential for these SLN to improve oral GEN bioavailability via intestinal lymphatic absorption.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article